Aaron Freidin serves as the Chief Financial Officer at GRAIL, Inc., a company focused on pioneering early cancer detection through innovative blood tests. With a robust background in finance and healthcare, Aaron has been instrumental in steering GRAIL towards its mission of transforming cancer care. Prior to joining GRAIL, Aaron held the position of CFO at Ardelyx, a biopharmaceutical company, where he played a pivotal role in its growth and financial strategy. His career also includes significant stints at companies such as Onyx Pharmaceuticals and Amgen, where he honed his skills in financial management and strategic planning within the biotech sector. At GRAIL, Aaron Freidin's role encompasses overseeing the company's financial operations, which includes managing capital allocation, financial planning, and investor relations. Under his leadership, GRAIL has successfully navigated the complex landscape of healthcare finance, securing substantial funding to support its research and development efforts. Aaron's strategic vision has been crucial in positioning GRAIL as a leader in the field of early cancer detection, helping the company forge partnerships and collaborations that enhance its technological capabilities and market reach. His contributions have not only bolstered GRAIL's financial health but also supported the company's broader goal of improving patient outcomes through cutting-edge medical technology.